A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 19];9(6):s631. Available from: https://skin.dermsquared.com/skin/article/view/3782